Theranica
Open enrollment with a later-stage pipeline tilt
According to ClinicalTrials.gov-derived indexes, Theranica sits in the top decile of US sponsors by registered trial count (#696 of 15,742 sponsors by registered trial count).
Theranica: 22 sponsored US clinical trials, 1 recruiting.
Theranica sponsors 22 registered US clinical trials on ClinicalTrials.gov, 1 of them currently recruiting, and 17 completed. 3 of these trials are in Phase 3-4 (later-stage) and 0 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Migraine, with 2 trials.
Top-decile sponsor footprint
Theranica ranks in the top decile of sponsors by registered trial count (#696 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
17 of 19 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (89.5%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
22 total, page 1 of 1
An Open Label Study Assessing REN Treatment in Headache Management in Temporomandibular Disorders
NCT07639944
Migraine Prevention With the Remote Electrical Neuromodulation (REN) Wearable: A Real-world Evidence Study
NCT07487701
Nerivio Efficacy Under High-Frequency Use
NCT07336056
Treatment Patterns Among US Veterans Using Remote Electrical Neuromodulation (REN) for Migraine Treatment
NCT07336420
Nerivio Efficacy by Time of Treatment Onset
NCT06976723
Machine Learning Assessment of Next-Day Migraine Likelihood
NCT07227194
Nerivio Long-term Usage in Patients With Migraine
NCT06738056
A Survey Study to Assess the Accessibility of the Nerivio Device At School
NCT06180577
Acute Treatment of Migraine in Pre-Adolescents: Real-World Analysis of Remote Electrical Neuromodulation (REN)
NCT06138756
A Prospective Post-marketing Observational Study Assessing the Safety and Efficacy of Nerivio for Migraine Prevention.
NCT05940870
Real World Data Analysis: Impact of High-Frequency REN Treatments As Migraine Preventive Therapy in Adolescence
NCT05769322
Real-World Evidence (RWE) Data Analysis of 1-year Consecutive Use of Remote Electrical Neuromodulation (REN)
NCT05760638
Safety of Nerivio in Pregnant Women With Migraine
NCT05464069
Real-world Data Analysis of REN Treatment in Migraine Patients
NCT04992897
Assessment of Safety and Efficacy of Nerivio for the Migraine Prevention
NCT04828707
Real-world Data Analysis of REN Treatment in Adolescence With Migraine
NCT05443659
Efficacy and Safety of Nerivio for the Acute Treatment of Menstrual Migraine
NCT04600388
Efficacy and Safety of Nerivio Device for Acute Treatment of Migraine in People With Chronic Migraine
NCT04194008
Safety and Efficacy of Nerivio™ for the Acute Treatment of Migraine in Adolescents
NCT04089761
Efficacy and Safety of Nerivio™ for Acute Treatment of Migraine in People With Chronic Migraine
NCT04161807
Evaluation of a Novel Device for Treatment of Migraine Headache
NCT03361423
Migraine Treatment With Nerivio Migra Neurostimulation Device
NCT03076515
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 4 | 3 |
Therapeutic Areas
Where Theranica enrollment is open (later-stage tilt)
1 recruiting of 22 indexed (5% open); 17 completed (77%).
Phase mix: 3 late (III/IV) vs 0 early (I/II) (later-stage heavy).
Top condition: Migraine (2 trials), 1 other listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Theranica: open-pipeline peers nationwide
Peers matched on 22 registered trials and 5% open enrollment, not the therapeutic-area sidebar.
Theranica sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 22 trials (± recruiting share)
- Alaunos Therapeutics · 22 trials · 0% recruiting
- Alexza Pharmaceuticals · 22 trials · 0% recruiting
- Calithera Biosciences · 22 trials · 0% recruiting
- Fate Therapeutics · 22 trials · 14% recruiting
Sponsors near 5% open enrollment (± trial volume)
- Johnson & Johnson Surgical Vision · 5% recruiting · 22 trials
- LEO Pharma · 5% recruiting · 65 trials
- Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections · 4% recruiting · 45 trials
- Galderma R&D · 4% recruiting · 158 trials
Related
What to do with this Theranica page
22 registered trials is a research-attention snapshot, not an endorsement of Theranica or any single study.
- 1 of Theranica's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Migraine is the condition Theranica studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Migraine trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Theranica pipeline card: 22 registered trials from official public datasets.Report a data error.